Cytovale competitors

Experienced public company CEO determined to leave the world a healthier place than when he arrived by developing new treatments for serious diseases and conditions.

Andre De Fusco is a Div President/CEO:ACT Networks at Clarent Corp, Chief Executive Officer at Cynvenio Biosystems Inc, and Board Member at Cynvenio Biosystems Inc. He has worked as Board Member at Isocor - Aglomerados de Cortiça, ACE; Board Member at Neven Vision; and President/CEO at Sabaeans. Andre works or has worked at Olivetti and Nortel Networks and works or has worked as President at Neven Vision and CHAIRMAN at Aircraft Electronics Association. He attended UCLA.

Cynthia Bamdad is a CEO at Minerva Biotechnologies and is based in Boston, Massachusetts. She has worked as Director at Pharmacyclics and CSO Clinical Micro Sensors, now Genmark at Minerva Biotechnologies. Cynthia works or has worked as BOARD MEMBER at Schl of Social Science, BOARD MEMBER at Urban Affairs and Public Policy, and BOARD MEMBER at Northeastern University. She attended Harvard University between 1992 and 1997 and Northeastern University.

Rolf is a dynamic biotechnology leader combining science and business knowledge to build and grow successful technology companies that further healthcare and the field of personalized medicine. He has structured and guided highly efficient multi-disciplinary research and commercial teams through funding, to product development and successful product launch into global markets. Over the last 16 years he has been involved in analyzing markets and developing strategies to position biotechnologies to maximize value. He has interacted with most of the major pharma and biotechnology companies to obtain funded development contracts, joint projects, and partnerships. Rolf developed the strategies for strong patent portfolios to secure innovation that is the bedrock of technology based companies. Rolf is an expert in translating technology into financial concepts and funding presentations to angel investors, early and mid-stage venture firms and late stage private equity firms. In addition to raising successfully capital from investors he also raised non-dilutive capital from CDC, NCI, NIH, DARPA, In-Q-Tel and DOD. Rolf stands by the belief that the company success is dependent on a team effort of employees, customers and investors.

Dr. Maynard Howe, as Stemedica Co-Founder and former Chief Executive Officer, brings a richly diverse background to the Company. Along with his brother, Roger, he had previously launched five successful ventures in the medical device, software, testing and measurement, quality and consulting fields. As Founder, Co-Chairman and CEO of Reliant Technologies, he led a team of scientists, engineers and physicians in developing, testing and launching the revolutionary medical laser for skin surgery known as Fraxel, an award winning medical laser technology that has resulted in defining a new category of science called fractional photothermolysis. This new science involves the role of lasers and the patient’s own stem cells in wound healing and derm/plastic surgery. The Fraxel laser, in conjunction with autologous and allogeneic stem cells, is currently being used in new clinical studies to treat scars, burn scars and diabetic ulcers. During his tenure at Reliant Technologies, the company achieved a strong intellectual property position with over 20 patents issued and 40 pending applications. In addition, Reliant had secured 13 FDA clearances, making it one of the premier market leaders with distribution in over 15 countries. While at Reliant, Dr. Howe also led the team responsible for securing funding from individual and institutional investors including: Three Arch Partners, Pinnacle Venture Partners, Meritech Capital Partners, Delphi Ventures and Comerica Bank. Within two months of filing its S1, Reliant was sold to Solta Medical, Inc., a publicly held company (SLTM) that has and continues to pioneer and define the aesthetic industry with its innovative technology. Prior to Reliant, Dr. Howe helped more than fifty Fortune 500 companies coordinate their company-wide quality and customer relationship initiatives. As a senior executive and co-founder of a leading customer and market research company, he was responsible for conducting extensive marketing and branding campaigns, market assessments and trend research in both business-to-business and business-to-consumer environments. Maynard is also co-founder and previous Chairman of BioPharma Scientific, LLC, specializing in the integration of pharmaceutical nanotechnology into the field of nutraceuticals. He has experience in setting up distribution and managing sales channels throughout North America, Europe and parts of Asia for several of the companies he has co-founded. Maynard holds a Bachelor of Science Degree, Master of Science Degree and a Doctorate in Psychology. His ability to recruit world leaders and industry experts and create a culture of innovation and teamwork has contributed to the successes achieved in the businesses he has co-founded and those in which he has provided services as a board member and consultant. Dr. Howe is the author and co-author of numerous articles and top selling business books. He is a nationally and internationally recognized speaker and lecturer. His benchmark book on quality, “Quality on Trial, Bringing Customer Relationships into Focus“, is in its second edition and has been published in several languages. His current book, which he is a co-author, “Miracle of Stem Cells: How Adult Stem Cells are Transforming Medicine“, is in its second printing and in the process of being translated into several languages. Other books include a five part implementation manual series, “Business to Business Marketing Management System“, published by McGraw-Hill. He is a diplomate of the American College of Forensic Examiners and an active Board Member of the USO. Previously he was a Board Member and Chairman of the Advanced Development Committee for Alliant International University. Dr. Howe continues to Chair Doctoral Dissertations in Clinical Psychology and as well as in related Behavioral Science Fields.